Journal profile · Genetics & Heredity
GENES CHROMOSOMES & CANCER
ISSN 1045-2257 · eISSN 1098-2264 · Wiley-Liss Inc. · UNITED STATES · Monthly · Founded 1989
GENES CHROMOSOMES & CANCER: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 2.28; hybrid open access; APC about USD 4,810; median 71 days to acceptance (82 articles, last 24 months); community-reported acceptance: moderate; 99 articles in 2025; indexed in SCIE and Scopus.
Scope
Aims, scope and focus
GENES CHROMOSOMES & CANCER is published by Wiley-Liss Inc. and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cancer Genomics and Diagnostics, Genomic variations and chromosomal abnormalities and Sarcoma Diagnosis and Treatment, together about 27.3% of its articles. (generated from OpenAlex topic counts and CAS ranking data)
One of the largest and most authoritative collections of online journals, books, and research resources, covering life, health, social, and physical sciences.
From the journal's Aims & Scope
Research area (LetPub): Genetics & Heredity
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cancer Genomics and DiagnosticsBiochemistry, Genetics and Molecular Biology9.9%
- Genomic variations and chromosomal abnormalitiesBiochemistry, Genetics and Molecular Biology9.8%
- Sarcoma Diagnosis and TreatmentMedicine7.6%
- Acute Myeloid Leukemia ResearchMedicine7.2%
- Genetic factors in colorectal cancerMedicine6.9%
- Genomics and Chromatin DynamicsBiochemistry, Genetics and Molecular Biology5.2%
- Chronic Lymphocytic Leukemia ResearchMedicine4.5%
- Lymphoma Diagnosis and TreatmentMedicine4.2%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Oncology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 3
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 3 |
| Minor | Oncology | Zone 3 |
| Minor | Genetics & Heredity | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Genetics & Heredity | Zone 2 |
| Minor | Oncology | Zone 2 |
Top journal: noReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 2.28LetPub ·
- CiteScore 2026-06
- 6LetPub ·
- SJR 2026-06
- 1.31LetPub ·
- SNIP 2026-06
- 1.18LetPub ·
- h-index
- 114LetPub ·
- h-index
- 159OpenAlex ·
- i10-index
- 3,405OpenAlex ·
- 2-year mean citedness
- 1.73OpenAlex ·
- Self-citation rate
- 4.3%LetPub ·
- Share of gold OA articles
- 50.7%LetPub ·
Volume
- Articles per year
- 70LetPub ·
Articles by year OpenAlex count · 5,174 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 78 | 39 | 19 |
| 2025 | 99 | 61 | 138 |
| 2024 | 98 | 56 | 320 |
| 2023 | 94 | 69 | 639 |
| 2022 | 113 | 59 | 1,224 |
| 2021 | 97 | 44 | 1,390 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
71 daysMedian, submission to acceptance · P25–P75 33 days – 103 days
- Acceptance to online
- median 15 days (82 articles)
- Submission to online
- median 89 days
- Sample
- 82 articles with submission and acceptance dates (179 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- 4–8 weeksLetPub ·
- Average acceptance (community reports)
- ModerateLetPub ·
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 4,810 / EUR 4,040 / GBP 3,220 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Wiley-Liss Inc.
- Country or region
- UNITED STATES
- Language
- English
- Frequency
- Monthly
- Founded
- 1989
- ISSN
- 1045-2257
- Electronic ISSN
- 1098-2264
- Official links
- Journal homepage ↗OpenAlex
- Submission system ↗LetPub
FAQ
Frequently asked questions about GENES CHROMOSOMES & CANCER
What CAS zone is GENES CHROMOSOMES & CANCER in?
In the 2025 upgraded edition of the CAS Journal Ranking, GENES CHROMOSOMES & CANCER is in Zone 2 of Medicine, and in Zone 2 of the minor category Genetics & Heredity / Oncology. In the 2026 Xinrui edition it is in Zone 3 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of GENES CHROMOSOMES & CANCER?
The latest impact factor listed by LetPub is 2.28; CiteScore 6, h-index 159.
How long does peer review take at GENES CHROMOSOMES & CANCER?
Based on the dates recorded on 82 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 71 days (interquartile range 33–103 days); authors report an average review time of 4–8 weeks; the community-reported acceptance is “Moderate”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index GENES CHROMOSOMES & CANCER?
According to LetPub and DOAJ records, GENES CHROMOSOMES & CANCER is indexed in SCIE and Scopus.
Is GENES CHROMOSOMES & CANCER open access, and what is the APC?
GENES CHROMOSOMES & CANCER is a hybrid journal. For open-access publication: APC about USD 4,810.
Sources and updates
The facts on this page come from LetPub, OpenAlex, Publisher website; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .